BritePear› 🍐 Peptide You› AOD-9604
Peptide You · Fat Metabolism
Compounding Gray Area, June 2026 Warning

AOD-9604: The Fat Fragment

The piece of human growth hormone that targets fat metabolism, without the blood sugar effects of full HGH.

🍐 Pear It Down ,

AOD-9604 is a synthetic fragment of human growth hormone (amino acids 176–191). It targets fat metabolism without affecting blood sugar or IGF-1 levels. It completed Phase II/III clinical trials but did not meet obesity drug approval endpoints. It holds an FDA GRAS designation for food use. Still investigational for weight loss. Currently being marketed in the gray market as a "semaglutide alternative." It is not.

Not medical advice. Educational information reflecting personal research and transparency. The gray market landscape around AOD-9604 is changing rapidly. Always work with a qualified healthcare provider before starting any protocol.
⚠ June 2026 Market WarningAOD-9604 is actively being rebranded in gray market channels as a "semaglutide alternative" or GLP-1 substitute. It is neither. It has no GLP-1 receptor activity. Read this page before making any decisions about this compound.

AOD-9604 has a backstory different from most peptides in this curriculum. It wasn't discovered in nature or stumbled upon in a research lab. It was deliberately engineered. Researchers at Monash University in Australia sat down with the growth hormone molecule and asked: which part is responsible for fat burning, and can we isolate it?

The Engineering

How It Was Designed

Human Growth Hormone has two distinct functional regions relevant to body composition. The N-terminus region drives anabolic effects, muscle growth, IGF-1 stimulation, changes to blood sugar and insulin sensitivity. The C-terminus region (specifically amino acids 176–191) appears to drive lipolysis, the breakdown of fat.[1]

AOD-9604 is a stabilized analog of that C-terminal fragment. The "AOD" designation comes from Anti-Obesity Drug. The goal was a compound that could use the fat-burning signal of HGH while avoiding the metabolic risks: elevated blood sugar, insulin resistance, and the known cancer-risk concerns associated with long-term HGH use.[2]

"For anyone on a GLP-1 journey thinking about body composition, the AOD-9604 conversation is interesting because it's targeting the fat metabolism pathway specifically, not trying to create muscle, not interfering with insulin. It's a narrow, targeted signal. What it is not is a substitute for GLP-1 therapy."

Clinical History

Where It Went Through Trials

AOD-9604 went further through the clinical trial process than most peptides discussed in Peptide You. Phase I and Phase II trials established safety and early efficacy signals for weight loss. Phase IIb trials showed statistically significant weight loss versus placebo at 12 weeks.[5] A Phase III trial was pursued but the compound did not achieve the endpoints needed for FDA obesity drug approval.

Here's the unusual part: despite not achieving drug approval, AOD-9604 was granted GRAS (Generally Recognized As Safe) status by the FDA for use as a food ingredient, a designation that reflects a meaningful safety evaluation even if it does not confer drug approval for weight loss.[6]

⚠ FDA / Regulatory StatusAOD-9604 holds FDA GRAS status as a food ingredient but is NOT approved as a drug for obesity or any indication. As a compounded pharmaceutical for injection, it is investigational. Its regulatory pathway for compounding has been debated. Given current gray market marketing activity around this compound, approach any vendor claims with heightened scrutiny.
Cliff's Note

The clinical trial experience gives AOD-9604 a different standing than many peptides in this curriculum. It has been through more rigorous human safety evaluation than most. The Phase III failure was about efficacy at scale, not safety concerns. For someone already on a GLP-1 medication, AOD-9604's targeted fat metabolism mechanism is an interesting complementary conversation, one worth raising specifically with your physician. It is not a replacement for your GLP-1. Full stop.

Sources & Citations

  1. Ng FM, et al. (1990). Metabolic studies of a growth hormone-releasing peptide. FEBS Letters, 258(2), 250–252.
  2. Heffernan MA, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Journal of Endocrinology, 168(2), 267–276.
  3. Heffernan MA, et al. (1999). Increase of fat oxidation and weight loss in obese mice. International Journal of Obesity, 23(12), 1286–1292.
  4. Ng FM & Bornstein J (1978). Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Endocrinology, 102(6), 1835–1842.
  5. Stier H, et al. (2013). Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism, 3(1–2), 7–15.
  6. US Food & Drug Administration. GRAS Notices. GRN No. 000528, AOD9604. fda.gov